Secondary Logo

Journal Logo

Editorial Comment

Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension?

Campese, Vito M.a; Bianchi, Stefanob; Bigazzi, Robertob

Author Information
Current Opinion in Nephrology and Hypertension: March 2000 - Volume 9 - Issue 2 - p 143-147
  • Free

Introduction

The term microalbuminuria refers to urinary albumin excretion (UAE) that is above the 95% confidence interval of the normal population, but that is below amounts detectable by semiquantitative methods (30-300 mg/24 h or 20-200 μg/min). In patients with insulin-dependent diabetes mellitus (IDDM), several studies [1-3] have indicated that microalbuminuria is a marker of glomerular damage, and strongly predicts the development of overt proteinuria and progressive renal failure. The predictive value of microalbuminuria for the development of renal damage in noninsulin-dependent diabetes mellitus (NIDDM) is less well established [4]. Increasing evidence also supports the notion that microalbuminuria predicts cardiovascular morbidity and mortality in both IDDM and NIDDM patients [5,6]. Recently, a large body of evidence has been published that suggests that the predictive value of microalbuminuria may extend to patients with essential hypertension.

The present review discusses the incidence of microalbuminuria in patients with essential hypertension, its relationship with blood pressure levels and other cardiovascular risk factors, and the evidence supporting its role in predicting cardiovascular as well as renal complications.

Prevalence of microalbuminuria and its relationship with blood pressure levels

The prevalence of microalbuminuria in patients with essential hypertension varies enormously among different studies, with rates ranging between 5 and 37% [7-11]. In a study of 11 343 nondiabetic hypertensive patients with a mean age of 57 years [12], microalbuminuria was present in 32% of men and 28% of women (P < 0.05) and increased with age, severity and duration of hypertension.

Most studies have shown a significant but weak correlation between UAE and office blood pressure, whereas a stronger correlation usually exists between average 24 h blood pressure measured using continuous ambulatory monitoring and UAE [13-15]. We have observed a blunted or absent nocturnal dipping of blood pressure in hypertensive patients with microalbuminuria compared with those with normal UAE and with normotensive healthy individuals [16]. This observation is relevant in light of evidence that nocturnal blood pressure correlates better than office blood pressure with cardiovascular complications [17-19] and silent cerebrovascular disease [20].

Pathogenesis of microalbuminuria in essential hypertension

The pathogenesis of microalbuminuria in patients with essential hypertension has not been established, and there are no studies available regarding the renal pathological findings associated with this abnormality. Most studies have focused on the role of increased glomerular hydrostatic pressure or increased permselectivity of the glomerular basement membrane.

Glomerular hydrostatic pressure is regulated by the relative vasoconstriction-vasodilatation of the afferent and efferent glomerular arterioles. Normally, an elevation in systemic arterial pressure is associated with vasoconstriction of the glomerular afferent arterioles, which prevents transmission of the elevated hydrostatic pressure to the glomerulus and maintains the glomerular hydrostatic pressure unaltered [21]. A large body of experimental and clinical evidence supports the notion that a derangement in these adaptive mechanisms may increase susceptibility to renal injury. Renal function deteriorates faster in salt-sensitive than in salt-resistant models of hypertension. In spontaneously hypertensive rats, a model of salt-resistant hypertension, the superficial nephrons adapt to the rise in blood pressure with an increase in renal afferent arteriolar resistance, which protects the kidneys from the adverse effects of arterial hypertension [22]. Dahl salt-sensitive rats, on the other hand, adapt to a rise in blood pressure with no change in the afferent arteriolar resistance, which results in increased glomerular capillary pressure, glomerulosclerosis and proteinuria [23].

In salt-sensitive patients with essential hypertension, we have observed renal haemodynamic derangements that are similar to those observed in the Dahl salt-sensitive rat. Renal blood flow decreased, and filtration fraction and intraglomerular pressure increased in salt-sensitive patients during high salt intake, whereas renal blood flow increased and filtration fraction and intraglomerular pressure decreased in salt-resistant individuals [24]. UAE was greater in salt-sensitive than in salt-resistant patients, and it was aggravated by a high salt intake [25]. In all, these studies suggest that microalbuminuria in essential hypertension could be the result of increased intraglomerular hydrostatic pressure, and high salt intake may aggravate this abnormality.

Microalbuminuria in patients with essential hypertension could also be due to alterations of the permselectivity of the glomerular basement membrane. Impaired glomerular charge selectivity has been observed even in healthy individuals with microalbuminuria [26]. The increased permeability of the glomerular basement membrane for albumin could be due to increased production by mesangial or endothelial cells of factors such as the vascular endothelial growth factor and the vascular permeability factor [27,28]. Vascular permeability factor is implicated in the pathogenesis of microalbuminuria and proteinuria in diabetic patients [29], and in patients with glomerulonephritis [30].

A good estimate of vascular permeability to albumin can be obtained from the measurement of the albumin transcapillary escape rate (TER). Patients with IDDM [31] and NIDDM microalbuminuria [32,33] manifest greater albumin TER than patients without microalbuminuria. An increase in albumin TER has been described in normotensive healthy individuals with microalbuminuria [34]. In patients with essential hypertension and microalbuminuria, Pedrinelli et al. [35] observed higher serum levels of von Willebrand factor, a marker of endothelial dysfunction, than in patients with normal UAE. In all, this evidence suggests that alterations in the permeability of endothelial cells can contribute to microalbuminuria in individuals with essential hypertension.

Microalbuminuria and serum lipids

In patients with essential hypertension, microalbuminuria is frequently associated with dislipidaemia, which is characterized by higher serum levels of low-density lipoprotein (LDL), triglycerides, apolipoprotein B, lipoprotein(a) and lower serum levels of high-density lipoprotein cholesterol [36-39].

On one hand, hyperlipidaemia could be secondary to increased urinary loss of protein. This is supported by the evidence that urinary losses of large amounts of proteins may lead to increased serum levels of total cholesterol and LDL-cholesterol [40,41] as well as lipoprotein (a) [42,43], and that microalbuminuria may be present in normotensive individuals with a genetic risk for diabetes [44] and hypertension [45]. On the other hand, microalbuminuria could be a consequence of renal damage caused by hyperlipidaemia. Evidence is mounting that lipid abnormalities may contribute to renal damage by accelerating atherosclerosis as well as intrarenal microvascular and macrovascular disease, thus contributing to the progression of renal disease [46,47]. Cholesterol-enriched diets may cause albuminuria and glomerulosclerosis in different animal species, particularly when combined with hypertension [48,49]. In addition, pharmacological agents that lower serum lipids ameliorate renal injury in several experimental models of renal disease [50]. The mechanism(s) responsible for the deleterious effects of lipids on glomerular injury are not well established. The resemblance between glomerular mesangial cells and vascular smooth muscle cells and the important role played by the latter cells in the process of atherosclerosis suggest that accumulation of lipids in the mesangial cells may cause or accelerate glomerulosclerosis [51]. Klahr et al. [52] have suggested that mesangial cells exposed to increased amounts of lipoproteins may incorporate lipids which, in turn, may stimulate their proliferation and results in the deposition of excessive glomerular basement membrane and progressive glomerulosclerosis. LDL can promote adherence of monocytes to endothelial cells, a potentially important factor in the progression of inflammatory glomerular diseases [53,54].

Microalbuminuria, insulin resistance and hyperinsulinaemia in essential hypertension

Several investigators have described the presence of insulin resistance and hyperinsulinaemia in a substantial number of patients with essential hypertension [55,56]. Some have suggested that hyperinsulinaemia may be associated with a greater risk of cardiovascular [57-59] and coronary artery diseases [60,61]. Several lines of evidence also suggest that hypertensive patients with hyperinsulinaemia excrete greater amounts of urinary albumin. We measured the plasma insulin response to an oral glucose load in patients with or without microalbuminuria and normotensive control individuals. In the hypertensive patients, the plasma insulin response to a glucose load (evaluated as the insulin area under the curve) was significantly enhanced compared with that in control individuals. Microalbuminuric patients had significantly higher insulin area under the curve values than patients with normal UAE [62]. Using the euglycaemic clamp technique, we have also observed a 35% reduction in the peripheral glucose uptake stimulated by insulin in patients with essential hypertension and microalbuminuria compared with in patients with normal UAE [63]. This appeared to be secondary to a reduction in glycogen synthesis, because the glucose oxidation was not altered.

The significance of the association between insulin resistance and microalbuminuria is uncertain. Because microalbuminuria and insulin resistance [64-67] occur in nondiabetic normotensive individuals with a genetic predisposition for hypertension, and hyperinsulinaemia and insulin resistance are genetically transmitted, microalbuminuria and enhanced plasma insulin response to glucose could both be genetically determined and cosegregate with the hypertensive status. Alternatively, insulin resistance and hyperinsulinaemia, or both, could be causally related to microalbuminuria. For example, insulin may alter glomerular haemodynamics directly or in association with other factors such as catecholamines, angiotensin II, glucagone and sodium [68]. Insulin could also increase UAE by altering glomerular membrane permeability, because the infusion of insulin increases UAE both in normal individuals and in patients with IDDM [69,70].

Microalbuminuria and cardiovascular disease

The increasing interest in the significance of microalbuminuria in essential hypertension derives, in large part, from the recognition that a rise in UAE is associated with an increased incidence of cardiovascular complications and morbid events, such as left ventricular hypertrophy [71-73], coronary heart disease [74-76], carotid artery thickness [77] and hypertensive retinopathy.

After a follow-up of 62-83 months, Damsgaard et al. [78] reported a greater incidence of strokes and other cardiovascular events in elderly nondiabetic individuals with increased UAE than in those with normal UAE. Other risk factors identified in this analysis were male sex and hypertension. The predictive value of microalbuminuria faded after the initial 5 years of follow-up.

Kuusisto et al. [79] studied the impact of hyperinsulinaemia and microalbuminuria, alone or in combination, on the incidence of cardiovascular events in 1069 elderly individuals followed for an average of 3.5 years. Of males 48% and of females 60.8% had hypertension. The incidence of fatal and nonfatal cardiovascular events was significantly greater in patients with microalbuminuria than in those without. By contrast, the incidence of cardiovascular events was only slightly, but not significantly increased in patients with higher serum insulin levels. The combined presence of microalbuminuria and hyperinsulinaemia increased the probability of fatal and nonfatal cardiovascular events, even after adjusting for other risk factors, such as male sex, cigarette smoking, hypertension and serum cholesterol levels.

In a study of 11 343 nondiabetic hypertensive patients, among patients with microalbuminuria 31% had coronary artery disease, 24% had left ventricular hypertrophy, 6% had had a stroke and 7% had peripheral vascular disease. In patients without microalbuminuria, these rates were 22, 14, 4 and 5%, respectively (P < 0.001). Furthermore, in patients with coronary artery disease, left ventricular hypertrophy, stroke and peripheral vascular disease, microalbuminuria was significantly greater than in patients who did not have these complications (P < 0.001) [12].

In a retrospective cohort analysis of 141 hypertensive individuals, after an average follow up of 7 years, we observed 12 cardiovascular events among the 54 patients with microalbuminuria and only two events among the 87 patients with normal UAE [80]. In a prospective cohort study of 631 individuals aged 50-75 years (54% of these patients had impaired glucose tolerance or NIDDM), Jager et al. [81] observed that microalbuminuria and peripheral arterial disease were both independent predictors of cardiovascular and all-cause mortality, especially among hypertensive individuals. In a prospective study of 2085 nondiabetic individuals [82], the relative risk of ischaemic heart disease associated with microalbuminuria was 2.3, and was independent of other conventional atherosclerotic risk factors.

Microalbuminuria and nephroangiosclerosis

One important question is whether microalbuminuria can predict the risk of progressive renal disease in patients with essential hypertension. There are no sufficient data to support this notion. After a follow-up of 5 years, Ruilope et al. [83] reported a decline of 11 ml/min in creatinine clearance among 24 hypertensive patients with microalbuminuria, as opposed to a decrease of only 2 ml/min in 49 hypertensive patients with normal UAE. In a retrospective cohort analysis of 141 hypertensive individuals followed for approximately 7 years [80], we observed that creatinine clearance decreased significantly more in patients with microalbuminuria than in those with normal UAE (−12.1 ± 2.77 versus −7.1 ± 0.88 ml/min, P < 0.05).

Larger prospective studies are necessary to determine whether microalbuminuria does predict the risk of end-stage renal disease in patients with essential hypertension.

References

1 Parving HH, Oxenboll B, Svendsen PA, Christensen JS, Andersen AR. Early detection of patients at risk of developing diabetic nephropathy: a longitudinal study of urinary albumin excretion. Acta Endocrinol 1982; 100:550-555.
2 Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 31:89-93.
3 Jones SL, Viberti GC. Hypertension and microalbuminuria as predictors of diabetic nephropathy. Diabetes Metab 1989; 15:327-332.
4 Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310:356-360.
5 Messent JW, Elliot TG, Hill RG, Jarret RJ, Keen H, Viberti GC. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three-year follow-up study. Kidney Int 1992; 41:836-839.
6 Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A ten-year follow-up study of 503 patients. Diabetes Med 1988; 5:126-134.
7 Parving HH, Jensen HE, Mogensen CE, Evrin PE. Increased urinary albumin excretion in benign essential hypertension. Lancet 1974; i:231-237.
8 Pedersen EB, Mogensen CE. Effect of antihypertensive treatment on urinary albumin excretion, glomerular filtration rate and renal plasma flow in patients with essential hypertension. Scand J Clin Lab Invest 1976; 36:231-237.
9 Bigazzi R, Bianchi S, Campese VM, Baldari G. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron 1992; 61:94-97.
10 Redon J, Liao Y, Lozano JV, Miralles A, Baldo E. Factors related to the presence of microalbuminuria in essential hypertension. Am J Hypertens 1994; 7:801-807.
11 Sprangler JG, Bell RA, Summerson JH, Konen JC. Correlates of abnormal urinary albumin excretion rates among primary care patients with essential hypertension. J Am Board Fam Pract 1997; 10:180-184.
12 Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14:223-228.
13 James A, Fotherby MB, Potter JF. Screening tests for microalbuminuria in non-diabetic elderly subjects and their relation to blood pressure. Clin Sci 1995; 88:185-190.
14 Giaconi S, Levanti C, Fommei E, Innocenti F, Seghieri G, Palla L, et al. Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild essential hypertension. Am J Hypertens 1989; 2:259-261.
15 Cerasola G, Cottone S, Mule G, Nardi E, Mangano MT, Andronico G, et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 1996; 14:915-920.
16 Bianchi S, Bigazzi R, Baldari G, Sgherri GP, Campese VM. Diurnal variation of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 1994; 7:23-29.
17 Sokolow M, Werdegar D, Kain HK, Hinman A. Relationship between level of blood pressure measured casually and by portable recorders and severity of complications in essential hypertension. Circulation 1966; 34:279-298.
18 Pickering TG, Devereux R. Ambulatory monitoring of blood pressure as a predictor of cardiovascular risk. Am Heart J 1987; 114:925-928.
19 Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81:528-536.
20 Shimada K, Kawamoto A, Matsubayashi K, Nishinaga M, Kimura S, Ozawa T. Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens 1992; 10:875-878.
21 Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a patential adverse response to renal ablation. Am J Physiol 1981; 241:F85-F93.
22 Raij L, Azar S, Keane WF. Role of hypertension in progressive glomerular immune injury. Hypertension 1985; 7:398-404.
23 Azar S, Limas C, Iwai J, Weller D. Single nephron dynamics during high Na+ intake and early hypertension in Dahl rats. Jpn Heart J 1979; 20(Suppl 1):138-140.
24 Campese VM, Parise M, Karubian F, Bigazzi R. Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension 1991; 18:805-812.
25 Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM. Microalbuminuria in salt-sensitive patients: a marker for renal and cardiovascular risk factors. Hypertension 1994; 23:195-199.
26 Jensen JS, Borch-Johnsen K, Deckert T, Deckert M, Jensen G, Feldt-Rasmussen B. Reduced glomerular size and charge-selectivity in clinically healthy individuals with microalbuminuria. Eur J Clin Invest 1995; 25:608-614.
27 Malek AM, Gibbons GH, Dzau VJ, Izumo S. Fluid shear stress differentially modulates expression of genes encoding basic fibroblast growth factor and platelet-derived growth factor B chain in vascular endothelium. J Clin Invest 1993; 92:2013-2021.
28 Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359:843-845.
29 Yeo TK, Senger DR, Dvorak HF, Freter L, Yeo KT. Glycosilation is essential for efficient secretion but not for permeability enhancing activity of vascular permeability factor. Biochem Biophys Res Commun 1991; 179:1568-1575.
30 Heslen JM, Branellec AI, Pilatte Y, Land P, Lagrue G. Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal change nephrotic syndrome. Clin Exp Immunol 1991; 86:157-162.
31 Nrgaard K, Jensen T, Feldt-Rasmussen B. Transcapillary escape rate of albumin in hypertensive patients with type I (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36:57-61.
32 Feldt-Rasmussen B. Increased transcapillary escape of albumin in Type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1986; 29:282-286.
33 Nannipieri M, Rizzo L, Rapuano A, Pilo A, Penno G, Navalesi R. Increased transcapillary escape of albumin in microalbuminuric type II diabetic patients. Diabetes Care 1995; 18:1-9.
34 Jensen JS, Borck-Johnsen K, Jensen J, Feldt Rasmussen B. Microalbuminuria reflects a generalized transvascular albumin leakness in clinically healthy subjects. Clin Sci 1995; 88:629-633.
35 Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G, Catapano G, et al. Microalbuminuria and endothelial disfunction in essential hypertension. Lancet 1994; 344:14-18.
36 Nosadini R, Cipollina MR, Solini A, Sambataro M, Morocutti A, Doria A, et al. Close relationship between microalbuminuria and insulin resistance in essential hypertension and non-insulin dependent diabetes mellitus. J Am Soc Nephrol 1992; 3(Suppl 1):S56-S63.
37 Mimran A, Ribstein J, DuCailar G. Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension? Hypertension 1994; 23:1018-1021.
38 Pontremoli R, Sofia A, Ravera M, Nicoletta C, Viazzi F, Tirotta A, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: The MAGIC Study. Microalbuminuria: a Genoa Investigation on complications. Hypertension 1997; 30:1135-1143.
39 Bigazzi R, Bianchi S, Nenci R, Baldari D, Baldari G, Campese VM. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens 1995; 9:827-833.
40 Kaysen GA. Hyperlipidemia of the nephrotic syndrome. Kidney Int 1991; 3(Suppl 31):S8-S15.
41 Keane WF, St Peter JV, Kasiske BL. Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? Kidney Int 1992; 42(Suppl 38):S134-S141.
42 Newmark SR, Anderson CF, Donadio JV, Ellefson RD. Lipoprotein profiles in adult nephrotics. Mayo Clin Proc 1975; 50:359-366.
43 Karådi I, Romics L, Pålos G, Domån J, Kaszås I, Hesz A, Kostner GM. Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 1989; 10:2121-2123.
44 Seaquist ER, Goetz FC, Rich S, Barbosa J. Familiar clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320:1161-1165.
45 Grunfeld B, Perelstein E, Simsolo R, Gimenez M, Romero JC. Renal functional reserve and microalbuminuria in offspring of hypertensive parents. Hypertension 1990; 15:257-261.
46 Keane WF. Lipids and the kidney. Kidney Int 1994; 46:910-920.
47 Tolins JP, Stone BG, Raij L. Interactions of hypercholesterolemia and hypertension in initiation of glomerular injury. Kidney Int 1992; 41:1254-1261.
48 Al-Shebeb T, Frohlich J, Magil AB. Glomerular disease in hypercholesterolemic guinea pigs: a pathogenic study. Kidney Int 1988; 33:498-507.
49 Groene HJ, Groene E, Luthe H, Weber MH, Helmchen V. Induction of glomerular sclerosis by a lipid-rich diet in male rats. Lab Invest 1989; 60:433-446.
50 Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP. Hyperlipidemia and progressive renal disease. Kidney Int 1991; 39(Suppl 31):S41-S48.
51 Rovin BH, Tan LC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 1993; 43:218-225.
52 Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988; 318:1657-1666.
53 Alderson LM, Endemann G, Lindsey S, Pronczuk A, Hoover RL, Hayes KC. LDL enhances monocyte adhesion to endothelial cells in vitro. Am J Pathol 1986; 123:334-342.
54 Pai R, Kirschenbaum MA, Kamanna VS. Low density lipoprotein stimulates the expression of macrophage colony-stimulating factor in glomerular mesangial cells. Kidney Int 1995; 48:1254-1262.
55 Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Eng J Med 1987; 317:350-357.
56 Swislocki AL, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989; 2:419-423.
57 Zavaroni I, Bonora E, Pagliara M, Dall'Aglio E, Luchetti L, Buonanno G, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320:702-706.
58 Fuller JH, Shipley MJ, Rose G, Jarrett RJ Keen H. Coronary heart disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980; 1:1373-1376.
59 Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, et al. Hyperinsulinemia. A link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75:809-817.
60 Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, Rosselin GE. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res 1985; 15:41-46.
61 Stern MP, Haffner SM. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 1986; 6:123-130.
62 Bianchi S, Bigazzi R, Valtriani C, Chiapponi I, Sgherri G, Baldari G, et al. Elevated serum insulin levels in patients with essential hypertension and microalbuminuria. Hypertension 1994; 23:681-687.
63 Bianchi S, Bigazzi R, Quinones Galvan A, Muscelli E, Baldari G, Pecori N, et al. Insulin resistance in microalbuminuric hypertension: sites and mechanism. Hypertension 1995; 26:789-795.
64 Ferrari P, Weidmann P, Shaw S, Giachino D, Riesen W, Alleman Y, Heynen G. Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. Am J Med 1991; 91:589-596.
65 Falkner B, Hulmans S, Tannembaum J, Kushner H. Insulin resistance in young black men. Hypertension 1990; 16:706-711.
66 Ohno Y, Suzuki H, Yamakawa H, Nakamura M, Otsuka K, Saruta T. Impaired insulin sensitivity in young, lean normotensive offspring of essential hypertensives : possible role of disturbed calcium metabolism. J Hypertens 1993; 11:421-426.
67 Grunfeld B, Balzareti M, Romo M, Gimenez M, Gutman R. Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension 1994; 23(1 Suppl 1):I12-I15.
68 Sholey JW, Meyer TW. Control of glomerular hypertension by insulin administration in diabetic rats. J Clin Invest 1989; 83:1384-1389.
69 Hilsted J, Christensen NJ. Dual effect of insulin on plasma volume and transcapillary albumin transport. Diabetologia 1992; 35:99-103.
70 Mogensen CE, Christensen NJ, Gundersen HJG. The acute effects of insulin on hearth rate, blood pressure, plasma noradrenaline and urinary albumin excretion. Diabetologia 1980; 18:453-457.
71 Redon J, Gomez-Sanchez MA, Baldo E, Casal MC, Fernandez ML, Miralles A, et al. Microalbuminuria is correlated with left ventricular hypertrophy in male hypertensive patients. J Hypertens 1991; 9(Suppl 6):S148-S149.
72 Pedrinelli R, Bello VD, Catapano G, Talarico L, Materazzi F, Santoro G, et al. Microalbuminuria is a marker of left ventricular hypertrophy but not hyperinsulinemia in non diabetic atherosclerotic patients. Arterioscler Thromb 1993; 13:900-906.
73 Cerasola D, Cottone S, D'Ignoto G, Grasso L, Mangano MT, Carapelle E, et al. Microalbuminuria as a predictor of cardiovascular damage in essential hypertension. J Hypertens 1989; 7(Suppl 6):S332-S333.
74 Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988; ii:530-533.
75 Agewall S, Persson B, Samuelsson O, Ljungman S, Herlitz H, Fageberg B. Microalbuminuria in treated hypertensive men at high risk of coronary disease. The Risk Factor Intervention Study Group. J Hypertens 1993; 11:461-469.
76 Horton RC, Gosling P, Reeves CN, Payne M, Nagle RE. Microalbumin excretion in patients with positive exercise electrocardiogram tests. Eur Heart J 1994; 15:1353-1355.
77 Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991; 11:1245-1249.
78 Damsgaard EL, Froland A, Jorgensen OD, Mogensen CE. Prognostic value of urinary albumin excretion rate and other risk factors in elderly diabetic patients and non-diabetic control subjects surviving the first 5 years after assessment. Diabetologia 1993; 36:1030-1036.
79 Kuusisto J, Mykkanen L, Pyorealea K, Laakso M. Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease. Circulation 1995; 9:831-837.
80 Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension predicts. J Hypertens 1998; 16:1325-1333.
81 Jager A, Kostense PJ, Ruhe' HG, Heine RJ, Nijpels G, Dekker JM, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects. Five-year follow-up of the Hoorn study. Arterioscler Thromb Vasc Biol 1999; 19:617-624.
82 Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Scroll M, Jensen JS. Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19:1992-1997.
83 Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia Robles R, Rodicio JL. Blood pressure and renal function: therapeutic implications. J Hypertens 1996; 14:1259-1263.
© 2000 Lippincott Williams & Wilkins, Inc.